Johnson & Johnson $JNJ Shares Sold by Janney Capital Management LLC

Janney Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the second quarter, HoldingsChannel reports. The firm owned 88,716 shares of the company’s stock after selling 692 shares during the quarter. Janney Capital Management LLC’s holdings in Johnson & Johnson were worth $13,551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Claris Advisors LLC MO raised its position in Johnson & Johnson by 57.4% during the 2nd quarter. Claris Advisors LLC MO now owns 3,437 shares of the company’s stock worth $525,000 after buying an additional 1,254 shares during the last quarter. Smith Chas P & Associates PA Cpas raised its holdings in shares of Johnson & Johnson by 2.4% during the second quarter. Smith Chas P & Associates PA Cpas now owns 259,477 shares of the company’s stock worth $39,635,000 after purchasing an additional 6,126 shares during the last quarter. Baron Silver Stevens Financial Advisors LLC lifted its position in Johnson & Johnson by 3.8% during the second quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,667 shares of the company’s stock valued at $866,000 after purchasing an additional 205 shares during the period. Prepared Retirement Institute LLC boosted its holdings in Johnson & Johnson by 23.0% in the second quarter. Prepared Retirement Institute LLC now owns 1,623 shares of the company’s stock valued at $248,000 after purchasing an additional 304 shares during the last quarter. Finally, Nova R Wealth Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $862,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $185.40 on Wednesday. The firm’s fifty day simple moving average is $175.11 and its two-hundred day simple moving average is $162.34. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $185.99. The company has a market cap of $446.51 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 2.31 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $181.40.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.